Detecting ALK, ROS1 and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small cell lung cancer patients using RNA-based techniques.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular oncology"
DOI: 10.1002/1878-0261.13468
Abstract: ALK, ROS1 and RET fusions and MET∆ex14 variant associate with response to targeted therapies in non-small cell lung cancer (NSCLC). Technologies for fusion testing in tissue must be adapted to liquid biopsies, which are often… read more here.
Keywords: alk ros1; ros1 ret; met ex14; liquid biopsies ... See more keywords
Abstract 4256: Multiplex fast FISH assay for detecting ROS1, RET and MET aberrations in FFPE specimens using BioView image analysis
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-4256
Abstract: Background: Biomarker testing in lung cancer is often limited by a lack of sufficient formalin fixed, paraffin embedded (FFPE) tissue for comprehensive genomic profiling. To promote personalized therapy for lung cancer, a multiplex FISH assay… read more here.
Keywords: fish assay; analysis; ret met; ros1 ret ... See more keywords
Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.
Sign Up to like & getrecommendations! Published in 2017 at "Clinical chemistry"
DOI: 10.1373/clinchem.2016.265314
Abstract: BACKGROUND Anaplastic lymphoma receptor tyrosine kinase (ALK), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), and ret proto-oncogene (RET) fusions are present in 5%-7% of patients with advanced non-small-cell lung cancer (NSCLC); their accurate identification is… read more here.
Keywords: advanced non; ret fusions; alk ros1; ros1 ... See more keywords
Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.18408
Abstract: Targeted therapies have substantially changed the management of non-small cell lung cancer (NSCLC) patients with driver oncogenes. Given the high frequency, EGFR and ALK aberrations were the first to be detected and paved the way… read more here.
Keywords: non squamous; alk; ros1 ret; ret positive ... See more keywords